| Literature DB >> 17715333 |
Jim J Gray1, Evelyne Kohli, Franco M Ruggeri, Harry Vennema, Alicia Sánchez-Fauquier, Eckart Schreier, Chris I Gallimore, Miren Iturriza-Gomara, Helene Giraudon, Pierre Pothier, Ilaria Di Bartolo, Nadia Inglese, Erwin de Bruin, Bas van der Veer, Silvia Moreno, Vanessa Montero, Marí C de Llano, Marina Höhne, Sabine M Diedrich.
Abstract
A total of 2,254 fecal samples were tested in a European multicenter evaluation of commercially available norovirus antigen detection assays. Two commercial enzyme immunoassays, IDEIA Norovirus (Oxoid; Thermo Fisher Scientific, Ely, United Kingdom) and RIDASCREEN Norovirus (R-Biopharm, Darmstadt, Germany), were included in the evaluation, and their performance was compared with the results of reverse transcription-PCR (RT-PCR). Included in the evaluation were samples collected in sporadic cases of gastroenteritis, samples from outbreaks in which two or more samples were collected, well-characterized samples representing genotypes currently cocirculating within Europe, and samples collected from patients with gastroenteritis caused by a pathogen other than norovirus. The sensitivities and specificities of the IDEIA Norovirus and RIDASCREEN Norovirus assays were 58.93 and 43.81% and 93.91 and 96.37%, respectively, compared with RT-PCR. The sensitivities of both assays for outbreak investigations improved when six or more samples from an outbreak were examined. The IDEIA Norovirus assay exhibited reactivity to a broader range of norovirus genotypes than the RIDASCREEN Norovirus assay, which showed genotype-dependent sensitivities. The results indicate that, if used, these assays should serve as screening assays and the results should be confirmed by RT-PCR.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17715333 PMCID： PMC2168115 DOI： 10.1128/CVI.00214-07
Source DB: PubMed Journal: Clin Vaccine Immunol ISSN： 1556-679X